✨ Free AI Report
aTyr Pharma: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research aTyr Pharma
Company Research

aTyr Pharma: Business Overview, Financials & Competitive Analysis

aTyr Pharma scores 6/10 on the AskCyborg Cyborg Score (Solid). Pivotal Phase 3 data and FDA meetings position efzofitimod for potential breakthrough therapy in orphan pulmonary indications, with Japan partnership providing value inflection. aTyr demonstrates clinical-stage progress with Phase 3 data readout imminent and multiple rare disease designations. The partnership with Kyorin provides near-term revenue potential. However, the company remains.

What is aTyr Pharma's industry? aTyr Pharma (atyrpharma.com) operates in Biopharmaceutical - Orphan/Rare Disease. AskCyborg classifies aTyr Pharma under Biopharmaceutical - Orphan/Rare Disease in its company registry.

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. The company's primary focus is efzofitimod (AT...

6/ 10Solid

Cyborg Score thesis

Pivotal Phase 3 data and FDA meetings position efzofitimod for potential breakthrough therapy in orphan pulmonary indications,...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Orphan/Rare Disease
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest aTyr Pharma Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for aTyr Pharma

AskCyborg analysts argue the bull and bear cases for aTyr Pharma across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
aTyr Pharma OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

aTyr Pharma Overview

Pro stress-test →

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. The company's primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate designed to down-regulate immune engagement in severe inflammatory lung diseases.

Strategic Profile

Pro stress-test →

The company was founded in 2005 and is headquartered in San Diego, California. aTyr has scheduled an FDA Type C Meeting for mid-April 2026 to review Phase 3 EFZO-FIT study results from pulmonary sarcoidosis. aTyr has a partnership with Kyorin Pharmaceutical with a total deal value up to $175M for development and commercialization of efzofitimod for ILD in Japan.

Competitive Landscape

Pro stress-test →

aTyr competes in the orphan lung disease therapeutic space with companies developing immunomodulatory and anti-fibrotic agents. The company's proprietary tRNA synthetase platform provides differentiation, though competitors in ILD treatment include established players focused on pirfenidone and nintedanib mechanisms. First-mover advantage in NRP2 modulation provides competitive positioning.

Industry Context

aTyr Pharma operates in Biopharmaceutical - Orphan/Rare Disease.

Key facts

Founded: 2005 · Headquarters: San Diego, United States · Employees: 49

What the analysts stress-tested

The top findings that survived the multi-agent debate for aTyr Pharma.

  • Phase 3 EFZO-FIT trial in pulmonary sarcoidosis completed with FDA Type C meeting scheduled for April 2026
  • Multiple orphan drug designations (US, EU, Japan) and Fast Track status provide regulatory advantages and potential accelerated pathways
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026FDA Type C Meeting scheduled for mid-April 2026 to discuss EFZO-FIT Phase 3 results in pulmonary sarcoidosis
  • Feb 2026Inducement grants announced under Nasdaq Listing Rule 5635(c)(4)
  • +1 moreTrack every material event for aTyr Pharma as it happens. Explore monitoring →
Get alerted when aTyr Pharma has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

PirfenidoneAnti-fibrotic approved for IPF; competitive standard of care→NintedanibTyrosine kinase inhibitor approved for multiple ILD indications→ApremilastPhosphodiesterase-4 inhibitor for systemic sclerosis and ILD→

Compare aTyr Pharma with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

aTyr Pharma operates in Biopharmaceutical - Orphan/Rare Disease. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Orphan/Rare Disease research →
NEW · MCP server

Ask your AI assistant about aTyr Pharma

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare aTyr Pharma and its top competitor on Cyborg Score”
“What did aTyr Pharma do this quarter?”
“Is aTyr Pharma a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does aTyr Pharma do?+
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. The company's primary focus is efzofitimod (AT...
What is aTyr Pharma's Cyborg Score?+
aTyr Pharma has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are aTyr Pharma's main competitors?+
Named competitors include Pirfenidone, Nintedanib, Apremilast. The full competitive landscape is in the AskCyborg report.
How can I get the full aTyr Pharma research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the aTyr Pharma research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track aTyr Pharma over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Orphan research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6aTyr Pharma